MedTrace Logo

Assessment of [18F]MNI-1054 as a Marker for LSD1

NCT03695926 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2019-05-23

No results posted yet for this study

Summary

The primary objective of this protocol is to evaluate \[18F\]MNI-1054 as a Lysine-specific histone demethylase 1A (LSD1) enzyme targeted radiopharmaceutical.

Conditions

  • Healthy Volunteers (HV)

Interventions

DRUG

[18F]MNI-1054

Healthy volunteers recruited for the study will undergo a \[18F\]MNI-1054 PET scan.

Sponsors & Collaborators

  • Invicro

    lead OTHER

Principal Investigators

  • Jennifer Madonia, PA-C · Invicro

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-09
Primary Completion
2019-05-02
Completion
2019-05-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03695926 on ClinicalTrials.gov